Treating neuropsychiatric symptoms in dementia with Lewy bodies: A randomized controlled-trial

Alzheimer Disease and Associated Disorders

Volumn 24, Issue 4, 2010, Pages 360-364

  Culo, Sandi ^a   Mulsant, Benoit H ^b,d   Rosen, Jules ^d   Mazumdar, Sati ^e   Blakesley, Richard E ^d   Houck, Patricia R ^d   Pollock, Bruce G ^b,c,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c ROTMAN RESEARCH INSTITUTE   (Canada)

^d Department of Psychiatry   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer disease; Dementia; Dementia with Lewy bodies; Neuropsychiatric symptoms; Pharmacotherapy

Indexed keywords

BENZODIAZEPINE; CITALOPRAM; LORAZEPAM; RISPERIDONE; NEUROLEPTIC AGENT;

AGED; ARTICLE; BEHAVIOR DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; COMPLICATION; LEWY BODY DISEASE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME; VERY ELDERLY;

AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CITALOPRAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME;

EID: 78651400870     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3181e6a4d7     Document Type: Article

References (32)

1. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996;47:1113-1124.
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
3. Ballard CG, Jacoby R, Del ST, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry. 2004;161:843-849.
4. Stavitsky K, Brickman AM, Scarmeas N, et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2006;63:1450-1456.
5. Baskys A. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry. 2004;65(suppl 11):16-22.
6. McKeith I, Del ST, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2000;356:2031-2036.
7. Cummings JL, Street J, Masterman D, et al. Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. Dement Geriatr Cogn Disord. 2002;13:67-73.
8. Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356-1363.
9. Luckhaus C, Jacob C, Reif A. Mirtazapine completely relieves severe insomnia in a patient with Lewy body dementia. Int J Psychiatry Clin Prac. 2003;7:139-141.
10. Tanaka M, Kita T. Paroxetine and improvement of visual hallucinations in patients with dementia with lewy bodies. J Am Geriatr Soc. 2005;53:732-733.
11. Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies-response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007;23:307-311.
12. Pollock BG, Mulsant BH, Rosen J, et al. A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry. 2007;15:942-952.
13. Sultzer DL, Levin HS, Mahler ME, et al. Assessment of cognitive, psychiatric, and behavioral disturbances in patients with dementia: the Neurobehavioral Rating Scale. J Am Geriatr Soc. 1992;40:549-555.
14. Wood S, Cummings JL, Hsu MA, et al. The use of the NeuroPsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry. 2000;8:75-83.
15. Auer SR, Monteiro IM, Reisberg B. The empirical behavioral pathology in Alzheimer's disease (E-BEHAVE-AD) rating scale. Int Psychogeriatr. 1996;8:247-266. (Pubitemid 27042906)
16. US Department of Health EaWAA. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: NIMH; 1976.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
18. Saxton J, McGonigle-Gibson KL, Swihart AA, et al. Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery. psychological assessment. J Consulting Clin Psychol. 1990;2:298-303.
19. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
20. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
21. Little RJA, Rubin DB. Statistical Analysis With Missing Data. New York: John-Wiley & Sons; 1987.
22. Mazumdar S, Tang G, Houck PR, et al. Statistical analysis of longitudinal psychiatric data with dropouts. J Psychiatric Res. 2007;41:1032-1041.
23. McKeith IG, Ballard CG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet. 1995;346:699.
24. Ballard C, Grace J, McKeith I, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet. 1998;351:1032-1033.
25. Sechi G, Agnetti V, Masuri R, et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies. Prog Neuropsychopharmacol Biol Psychiatry. 2000;24:1043-1051.
26. Morikawa M, Kishimoto T. Probable dementia with Lewy bodies and risperidone-induced delirium. Can J Psychiatry. 2002;47:976.
27. Tarawneh R, Galvin JE. Distinguishing Lewy body dementias from Alzheimer's disease. Expert Rev Neurother. 2007;7:1499-1516.
28. Collins B, Constant J, Kaba S, et al. Dementia with Lewy bodies: implications for clinical trials. Clin Neuropharmacol. 2004;27:281-292.
29. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry. 1990;157:894-901.
30. Gottfries CG, Nyth AL. Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. Ann N Y Acad Sci. 1991;640:276-279.
31. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107-115.
32. Bhasin M, Rowan E, Edwards K, et al. Cholinesterase inhibitors in dementia with Lewy bodies: a comparative analysis. Int J Geriatr Psychiatry. 2007;22:890-895.